| Project/Area Number |
20790101
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
KAKUTA Hiroki Okayama University, 大学院・医歯薬学総合研究科, 准教授 (80362961)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2009: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2008: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Keywords | 医薬分子設計 / 希少疾病 / 潰瘍性大腸炎 / クローン病 / レチノイドX受容体 / レチノイン酸受容体 / in vivo評価 / 核内受容体 / レチノイドX受容体(RXR) / レチノイン酸受容体(RAR) / DSS潰瘍性大腸炎マウスモデル |
|---|
| Research Abstract |
The objective of this research is to produce new compounds effective against inflammatory orphan diseases including inflammatory bowel disease or Crohn disease. Production of new anti-inflammatory compounds was performed by targeting nuclear receptors, retinoid X receptors (RXRs) and retinoic acid receptors (RARs).As a result, RXR agonists were found to show anti-inflammatory activity against DSS-induced and TNBS induced mice colitis.
|
